FAS and cancer: Although CD36, SREBPs, PD-L1/2, FABP5, CPT-1, ACC1, GLUT1, and FAS has shown promising prospects to be potential metabolic drug targets of cancer, their context-dependence and varied implications in T-cell subtypes urge for more research.